Daiichi Sankyo to boost ADC manufacturing; Eli Lilly looks to outer space; new FDA initiative for manufacturing tech
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential updates on new builds, collaborations, recalls and more. This week, we look into Eli Lilly joining Redwire’s initiative to manufacture pharmaceuticals in space, as well as Exela Pharma’s recall of three injectables.
Daiichi Sankyo boosts ADC capacity
Daiichi Sankyo is absorbing two of its wholly-owned manufacturing companies, Daiichi Sankyo Propharma and Daiichi Sankyo Chemical Pharma, effective April 2025. Announced on Tuesday, the move expands Daiichi’s capacity to supply and manufacture antibody-drug conjugates, as well as develop new modalities.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.